Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.
Stoffel ST, von Moos R, Thürlimann B, Cathomas R, Gillessen S, Zürrer-Härdi U, von Briel T, Anchisi S, Feller A, Schär C, Dietrich D, Schwenkglenks M, Lupatsch JE, Mark MT. Stoffel ST, et al. Among authors: schwenkglenks m. Swiss Med Wkly. 2021 Mar 1;151:w20464. doi: 10.4414/smw.2021.20464. eCollection 2021 Mar 1. Swiss Med Wkly. 2021. PMID: 33705559 Free article.
Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06).
Matter-Walstra K, Schwenkglenks M, Betticher D, von Moos R, Dietrich D, Baertschi D, Koeberle D. Matter-Walstra K, et al. Among authors: schwenkglenks m. Clin Colorectal Cancer. 2016 Dec;15(4):314-320.e2. doi: 10.1016/j.clcc.2016.03.002. Epub 2016 Mar 31. Clin Colorectal Cancer. 2016. PMID: 27117056 Clinical Trial.
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ. Matter-Walstra K, et al. Among authors: schwenkglenks m. Breast Cancer Res Treat. 2016 Jul;158(1):51-57. doi: 10.1007/s10549-016-3822-z. Epub 2016 Jun 8. Breast Cancer Res Treat. 2016. PMID: 27277747
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.
Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R, Gautschi O; Swiss Group for Clinical Cancer Research. Matter-Walstra K, et al. Among authors: schwenkglenks m. J Thorac Oncol. 2016 Nov;11(11):1846-1855. doi: 10.1016/j.jtho.2016.05.032. Epub 2016 Jun 14. J Thorac Oncol. 2016. PMID: 27311996 Free article.
A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).
Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, Aebersold DM, Plasswilm L, Lupatsch JE; Swiss Group for Clinical Cancer Research (SAKK). Panje CM, et al. Among authors: schwenkglenks m. Radiother Oncol. 2018 Nov;129(2):257-263. doi: 10.1016/j.radonc.2018.07.017. Epub 2018 Aug 10. Radiother Oncol. 2018. PMID: 30104008 Clinical Trial.
244 results